Please login to the form below

Not currently logged in
Email:
Password:

S-A invests €350m in vaccine facility

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France.

The new centre, near to Lyon, will come under the remit of the group's vaccine division, Sanofi Pasteur and employ 200 people. The facility will produce 100 million doses of the novel dengue fever vaccine, which is currently under development, and expects to be operational by 2013.

"This new vaccine production centre is the largest investment ever made by sanofi-aventis. It illustrates our commitment to providing solutions to unmet medical needs such as dengue, a disease that potentially puts almost half of the world's population at risk," said Christopher A Viehbacher, CEO of sanofi-aventis.

He went on to say that, including this latest investment, sanofi-aventis has invested over €1bn in vaccine production in France since 2005.

The French company is keen to respond to increasing global health needs through innovation. Earlier this month, sanofi-aventis announced it has invested almost €200m to convert its pharmaceutical production site at Vitry-sur-Seine in France to produce monoclonal antibodies.

13th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics